Abstract:Thomas Bradbury, 1 Gian Luca Di Tanna, 1 Anish Scaria, 1 Allison Martin, 1 Fu-Qiang Wen, 2 Nan-Shan Zhong, 3 Jin-Ping Zheng, 3 Peter J Barnes, 4 Bartolome Celli, 5 Norbert Berend, 1 Christine R Jenkins 1 On behalf of the TASCS Investigators 1 Respiratory Group, The George Institute for Global Health, Sydney, NSW 2042, Australia; 2 West China Hospital, Sichuan University, Chengdu, People's Republic of China; 3 State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 4 National Heart & Lung Institute, Imperial College, London, UK; 5 Pulmonary and Critical Care Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Correspondence: Thomas Bradbury Respiratory Group, The George Institute for Global Health, Level 5, 1 King St, Newtown, Sydney, NSW 2042, Australia , Tel +61 2 8052 4413 , Email Background and Objectives: The burden of chronic obstructive pulmonary disease (COPD) disproportionately affects patients in low to middle-income countries. Although the Theophylline and Steroids in COPD Study (TASCS) showed no clinical benefit from administering low-dose theophylline and prednisone in COPD patients compared to placebo, it was hypothesized that those with elevated blood eosinophil counts would receive clinical benefit from the intervention. Methods: This was a post-hoc analysis of the TASCS dataset – a double-blinded, placebo-controlled trial conducted in patients with moderate–severe COPD in China. Participants were allocated 1:1:1 to low-dose oral theophylline (100mg bd) and prednisone (5mg qd; PrT), theophylline (100mg bd) and prednisone-matched placebo (TP), or double-matched placebo (DP) groups and followed-up for 48 weeks. A baseline count of ≥ 300 eosinophils/μL blood was categorized as elevated/eosinophilic, and the primary outcome was the annualized moderate-severe exacerbation rate. Results: Of 1487 participants eligible for analysis, 325 (22%) were eosinophilic. These participants were predominantly male (82%), had a mean (SD) age of 64 (± 8) years and a predicted forced expiratory volume in 1s (FEV 1 ) of 43% (± 16). The annualized moderate–severe exacerbation rate was significantly higher in the PrT group compared to the pooled results of the TP and DP groups (incidence rate ratio = 1.6; ([95% CI 1.06– 1.76]) p = 0.016). Changes in spirometry values and reported disease impact scores (St. George's Respiratory Questionnaire and COPD Assessment Test) at week 48 were not significantly different between groups. Conclusion: Combination low-dose theophylline and prednisone was associated with a significant increase in the annual moderate-severe exacerbation rate in participants with a blood eosinophil count ≥ 300 cells/μL compared to placebo. Keywords: eosinophil, COPD, clinical trial, China, theophylline, prednisone Chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality worldwide, with an estimated prevalence of approximately 3% of the global community in 2019. 1 Current guidelines recommend use of long-acting bronchodilators to reduce symptoms and exacerbations, with the addition of inhaled corticosteroids when exacerbations become more frequent, particularly if blood eosinophil counts are raised above 300 cells/μL. 2 For significant portions of the global patient population, these pharmacotherapies are often under-utilized due to limited access and affordability – necessitating the use of low-cost alternatives where available. Previous in vitro and in vivo studies had suggested that the activity of histone deacetylase-2 (HDAC2), a nuclear enzyme that inhibits inflammatory gene expression, is markedly reduced in COPD. By interfering with the anti-inflammatory effects of corticosteroids, HDAC2 can be increased by low concentrations of theophylline, restoring corticosteroid responsiveness. 3–6 Thus, it was hypothesized that theophylline could promote anti-inflammatory gene expression and restore sensitivity to glucocorticosteroids in COPD patients, hence improving their response to prednisone. In the absence of access to gold standard bronchodilator therapy, this pharmacologic synergism could potentially provide an affordable and highly accessible management strategy for COPD patients in resource-poor settings. The "Theophylline And Steroids in COPD Study" (TASCS) was a multicenter randomized control trial undertaken in China to determine if the effect observed in vitro translated into cli -Abstract Truncated-

The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial

Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial

Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis

Multicentre double-blind randomised controlled trial of systematic corticosteroid therapy in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to hospital with higher eosinophil levels: the ECHO protocol

Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis

Systemic Corticosteroid Forcopdexacerbations, Whether the Higher Dose is Better? A Meta‐analysis of Randomized Controlled Trials

Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials

Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial

Efficacy and Safety of Jia Wei Bushen Yiqi Formulas As an Adjunct Therapy to Systemic Glucocorticoids on Acute Exacerbation of COPD: Study Protocol for a Randomized, Double-Blinded, Multi-Center, Placebo-Controlled Clinical Trial.

Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial.

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

Effect of Added Inhaled Corticosteroids to Systemic Steroids on COPD Exacerbation Outcomes

Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review

[The Effects and Therapeutic Duration of Oral Corticosteroids in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Diseases].

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

Comparison Of The Clinical Outcomes Between Nebulized And Systemic Corticosteroids In The Treatment Of Acute Exacerbation Of Copd In China (Contain Study): A Post Hoc Analysis

Long- versus short-duration systemic corticosteroid regimens for acute exacerbations of COPD: A systematic review and meta-analysis of randomized trials and cohort studies

[Efficacy and toxicity of short-course corticosteroid therapy in chronic bronchial diseases]